Opioid Prescription Trends for Migraine in Youth in the ED
The use of opioids in emergency departments for the management of migraine pain in adolescents and young adults was found to be common.
AHS 2019
Complete Coverage
Shift in Prescribing Patterns for Migraine Prophylaxis With the Emergence of Anti-CGRP Antibodies
Results of a survey on early prescribing patterns of emerging treatments for migraine prophylaxis indicate that clinicians anticipate decreased use of onabotulinumtoxinA and increased use of erenumab for episodic migraine treatment.
Telemedicine Comparable to In-Office Visits for Migraine Follow-Up Care
Long-term follow-up care for the management of migraine with severe disability using telemedicine was found to have comparable efficacy compared to in-office visits.
History of Migraine May Not Be Linked to Cardiovascular Events in Postmenopausal Women
A history of migraine in postmenopausal women may not be linked to an increased risk for stroke, myocardial infarction, or composite cardiovascular disease events.
Galcanezumab Ineffective for Chronic Cluster Headache Treatment
Treatment with monthly subcutaneous injections of galcanezumab 300 mg may not be effective for reducing weekly chronic cluster headache attack frequency.
Noninvasive Vagus Nerve Stimulation Studies More Consistently Adhere to IHS Guidelines
PHILADELPHIA — Adherence to International Headache Society (IHS) guidelines is most consistent in migraine and cluster headache studies focused on noninvasive vagus nerve stimulation, according to research presented at the American Headache Society 61st Annual Scientific Meeting, held July 11 to 14, 2019, in Philadelphia, Pennsylvania. This systematic review sourced 71 studies from Cochrane Library,…
Eptinezumab May Significantly Reduce Migraine-Related Burden in Chronic Migraine
Eptinezumab treatment for chronic migraine was associated with significant reduction in migraine-related burden on work, home, and social functioning.
Non-Invasive Device Stimulating Occipital and Trigeminal Nerves Effectively Treats Acute Migraine
Combined stimulation of the occipital and trigeminal nerves using a non-invasive stimulation device was found to be effective for the acute treatment of migraine.
Oral Atogepant May Reduce Mean Monthly Migraine Days
Atogepant was found to be safe and effective for reducing the mean monthly migraine days.
Single-Dose Rimegepant Provides Rapid, Sustained Relief From Migraine
A single dose of oral rimegepant may provide safe, fast, and sustained relief from migraine.
Promising Results for Lacosamide in the Treatment of Chronic Migraine
Lacosamide, an anti-epileptic drug that inhibits phosphorylation of collapsing response mediator protein 2 and blocks the release of calcitonin gene-related peptide in the trigeminal system, may be effective in the treatment of chronic migraine.
Ubrogepant Efficacious in Acute Migraine Treatment For Those in Whom Triptans Not Effective
Ubrogepant has demonstrated efficacy in treating acute migraine among individuals for whom triptan has not been effective.
OnabotulinumtoxinA Associated With Fewer Monthly Migraine Days in Those With Chronic Migraine
OnabotulinumtoxinA has demonstrated efficacy, safety, and tolerability in treating chronic migraine.
Want to read more?
Please login or register first to view this content.
Next post in AHS 2019 Meeting
